{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T23:33:45Z","timestamp":1776900825171,"version":"3.51.2"},"reference-count":19,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014841","name":"medac GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014841","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>L-Asparaginases (ASNases) are used for the treatment of acute lymphoblastic leukaemia. There are reports of quality problems for some therapeutic asparaginase products, especially those manufactured in middle-income countries. These products may exhibit decreased potency and\/or decreased specific activity, or an elevated level of impurities such as host cell proteins. In this study, four different ASNase preparations that were not modified with polyethylene glycol were compared in detail regarding their quality: Spectrila\u00ae, Celginase\u2122, Bionase\u00ae, and L-Aspase\u00ae. Samples were analyzed for protein content, impurities, and enzyme activity. Various chromatographic methods as well as mass spectrometry were used to assess purity and identity. Sample protein content, host cell protein, and enzyme activity showed some results that were out of target range for Celginase\u2122 and Bionase\u00ae. These ASNase preparations also showed detectable levels of endotoxins. In gel electrophoresis, additional bands were found for Bionase\u00ae. Size exclusion chromatography showed increased high and low molecular weight species for Bionase\u00ae and L-Aspase\u00ae, and reversed-phase chromatography showed increased hydrophilic and hydrophobic species for Bionase\u00ae. In capillary zone electrophoresis, increased retention time for L-Aspase\u00ae and increased levels of charge variants for Bionase\u00ae, Celginase\u2122, and L-Aspase\u00ae were seen. ASNase quality standards are crucial to ensure patient safety and product efficacy, as decreased potency and specific activity may affect efficacy in acute lymphoblastic leukaemia treatment, and increased impurities may affect immunogenicity. Out of four ASNase preparations tested in this study, only Spectrila\u00ae did not raise any quality concerns. The other three products exhibited quality problems, rendering them unsuitable according to established quality requirements defined in European and US guidelines for pharmaceutical development of parenteral drug products.<\/jats:p>","DOI":"10.1371\/journal.pone.0326106","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T17:28:38Z","timestamp":1750094918000},"page":"e0326106","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Physicochemical quality assessment of four asparaginases"],"prefix":"10.1371","volume":"20","author":[{"given":"Vanessa","family":"Radtke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Radcke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene","family":"Eichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja J.","family":"Pohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7942-0387","authenticated-orcid":true,"given":"Arndt","family":"Schnuchel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"pone.0326106.ref001","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fbioe.2018.00212","article-title":"Development of L-Asparaginase biobetters: current research status and review of the desirable quality profiles","volume":"6","author":"LP Brumano","year":"2019","journal-title":"Front Bioeng Biotechnol"},{"issue":"10","key":"pone.0326106.ref002","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.3324\/haematol.2017.165845","article-title":"Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951","volume":"102","author":"V Mondelaers","year":"2017","journal-title":"Haematologica"},{"key":"pone.0326106.ref003","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/nyas.12496","article-title":"Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia","volume":"1329","author":"WL Salzer","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"pone.0326106.ref004","doi-asserted-by":"crossref","first-page":"122523","DOI":"10.1016\/j.ijpharm.2022.122523","article-title":"A scoping review to compare and contrast quality assurance aspects of l-asparaginase biosimilars","volume":"632","author":"X Qin","year":"2023","journal-title":"Int J Pharm"},{"issue":"13","key":"pone.0326106.ref005","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1182\/blood-2008-04-149443","article-title":"Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial","volume":"112","author":"R Pieters","year":"2008","journal-title":"Blood"},{"issue":"1","key":"pone.0326106.ref006","first-page":"75","article-title":"A retrospective comparison of Escherichia coli and polyethylene glycol-conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemia","volume":"15","author":"J Liang","year":"2018","journal-title":"Oncol Lett"},{"key":"pone.0326106.ref007","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-020-00170-6","article-title":"Leukemia incidence trends at the global, regional, and national level between 1990 and 2017","volume":"9","author":"Y Dong","year":"2020","journal-title":"Exp Hematol Oncol"},{"issue":"11","key":"pone.0326106.ref008","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2020-003282","article-title":"Shortages and price variability of essential cytotoxic medicines for treating children with cancers","volume":"5","author":"YM Martei","year":"2020","journal-title":"BMJ Glob Health"},{"issue":"8","key":"pone.0326106.ref009","article-title":"The international scandal of defective asparaginase: A blight on children with cancer","volume":"70","author":"RD Barr","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"pone.0326106.ref010","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bjh.17494","article-title":"Influence of different asparaginase formulations in the prognosis of children with acute lymphocytic leukaemia in Brazil: a multicentre, retrospective controlled study","volume":"194","author":"MB Michalowski","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"pone.0326106.ref011","doi-asserted-by":"crossref","DOI":"10.1093\/biomethods\/bpae042","article-title":"Implementation of plate reader-based indooxine and Nessler protocols for monitoring L-asparaginase serum activity in childhood acute lymphoblastic leukaemia","volume":"9","author":"B Vergov","year":"2024","journal-title":"Biol Methods Protoc"},{"issue":"6","key":"pone.0326106.ref012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0285948","article-title":"Quality comparison of a state-of-the-art preparation of a recombinant L-asparaginase derived from Escherichia coli with an alternative asparaginase product","volume":"18","author":"A Schnuchel","year":"2023","journal-title":"PLoS One"},{"issue":"18","key":"pone.0326106.ref013","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1002\/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2","article-title":"Probability-based protein identification by searching sequence databases using mass spectrometry data","volume":"20","author":"DN Perkins","year":"1999","journal-title":"Electrophoresis"},{"issue":"1","key":"pone.0326106.ref014","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s13361-011-0261-2","article-title":"StavroX--a software for analyzing crosslinked products in protein interaction studies","volume":"23","author":"M G\u00f6tze","year":"2012","journal-title":"J Am Soc Mass Spectrom"},{"issue":"4","key":"pone.0326106.ref015","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.biotechadv.2018.03.021","article-title":"Host cell protein removal from biopharmaceutical preparations: Towards the implementation of quality by design","volume":"36","author":"CH Goey","year":"2018","journal-title":"Biotechnol Adv"},{"issue":"1","key":"pone.0326106.ref016","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10637-021-01173-8","article-title":"Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase","volume":"40","author":"T Modi","year":"2022","journal-title":"Invest New Drugs"},{"issue":"9","key":"pone.0326106.ref017","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(18)30584-9","article-title":"Monitoring asparaginase activity in middle-income countries","volume":"19","author":"DK Cecconello","year":"2018","journal-title":"Lancet Oncol"},{"key":"pone.0326106.ref018","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ebiom.2018.03.005","article-title":"Low bioavailability and high immunogenicity of a new brand of E. colil-Asparaginase with active host contaminating proteins","volume":"30","author":"PP Zenatti","year":"2018","journal-title":"EBioMedicine"},{"issue":"11","key":"pone.0326106.ref019","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29294","article-title":"Comment on: Unsatisfactory quality of E. coli asparaginase biogenerics in India: Implications for clinical outcomes in acute lymphoblastic leukaemia","volume":"68","author":"MB Michalowski","year":"2021","journal-title":"Pediatr Blood Cancer"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0326106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T17:28:45Z","timestamp":1750094925000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0326106"}},"subtitle":[],"editor":[{"given":"Oksana","family":"Lockridge","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0326106","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]}}}